Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.

Abstract: This invention offers isoxazole derivatives represented by the following formula (I) in which R1 and R2 each stands for hydrogen, lower alkyl, amino and the like; R3 stands for substituted or unsubstituted aryl or hetero aryl; R4 stands for hydrogen or lower alkyl; R5 stands for substituted or unsubstituted phenyl, furyl and the like; and Y stands for —CH2—, —CO—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof which exhibit excellent p38MAPkinase-inhibiting action with reduced side-effects, and are useful for treating such diseases as chronic rheumatoid arthritis, ulcerative colitis and the like.

Abstract: The invention discloses isoxazole derivatives represented by a formula, in which R1 stands for hydrogen, lower alkyl, amino, halogen, lower alkoxy and the like, R2 stands for substituted or unsubstituted aryl and the like, R3 stands for hydrogen or lower alkyl, R4 stands for substituted or unsubstituted phenyl and the like, and Y stands for —CH2—, —CO—, —CH(CH3)—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof, which have excellent p38MAPkinase inhibitory action.

Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.

Abstract: This invention offers isoxazole derivatives represented by the following formula (I) in which R1 and R2 each stands for hydrogen, lower alkyl, amino and the like; R3 stands for substituted or unsubstituted aryl or hetero aryl; R4 stands for hydrogen or lower alkyl; R5 stands for substituted or unsubstituted phenyl, furyl and the like; and Y stands for —CH2—, —CO—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof which exhibit excellent p38MAPkinase-inhibiting action with reduced side-effects, and are useful for treating such diseases as chronic rheumatoid arthritis, ulcerative colitis and the like.

Abstract: The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.

Abstract: The invention discloses isoxazole derivatives represented by a formula, in which R1 stands for hydrogen, lower alkyl, amino, halogen, lower alkoxy and the like, R2 stands for substituted or unsubstituted aryl and the like, R3 stands for hydrogen or lower alkyl, R4 stands for substituted or unsubstituted phenyl and the like, and Y stands for —CH2—, —CO—, —CH(CH3)—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof, which have excellent p38MAPkinase inhibitory action.

Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)-(A)n-Y, —CH2—CH(R4)-(A)n-Y, —CO-B1-A-Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group.

Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)-(A)n —Y, —CH2 —CH(R4)-(A)n—Y, —CO—B1-A-Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.

Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)—(A)n—Y, —CH2—CH(R4)—(A)n—Y, —CO—B1—A—Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.

Abstract: Aminopyrazole derivatives represented by formula (I), or salts thereof, wherein X1 and X2 are each a hydrogen atom or a halogen atom, or X1 and X2 may be united together to form a lower alkylenedioxy group, Q is a pyridyl group or a quinolyl group, R1 is a hydrogen atom, a substituted or unsubstituted lower alkyl or aryl group, R2 is a hydrogen atom, a lower alkyl group, or an aralkyl group, and R3 represents a hydrogen atom, an organic sulfonyl group, or —C(═Y)—R4 in which R4 is a hydrogen atom or an organic residue and Y is an oxygen or sulfur atom, provided that, when R3 is a hydrogen atom, R1 is a group other than a hydrogen atom and R2 is a hydrogen atom. These amimopyrazole derivatives or their salts have excellent p38MAP kinase inhibiting activities and are hence useful in the prevention or treatment of diseases associated with tumor necrosis sis factor &agr;, interleukin 1, interleukin 6 or cyclooxygenase II.

Abstract: A forklift has a frame and a rear axle, which is pivotally joined to the frame about a center pivot axis. Front and rear supporting members support the frame on the axle. A damper is located between the frame and the axle. The damper has an upper end connected to the frame and a lower end connected to the axle. A bracket for joining the upper end of the damper to the frame is located no further forward than the front end of the front support member and no further rearward than the rear support member. This structure suppresses torsion and bending force applied to the damper.

Abstract: The present invention discloses a differential axle housing which is particularly adapted for use in a fork lift and by which productivity is improved and which can be produced in a manner minimizing the wast of materials. Its differential housing has a generally cylindrical roll-forged ring portion having open ends along an axis, and a cover closing one of the open ends. A pair of straight cylindrical flange portions, preferably roll-forged, are attached in diametrically opposite relation to each other on the peripheral wall of the ring portion, each surrounding an axle opening therein. These elements are welded to the ring portion after being individually formed. Thus, the differential housing is produced. A pair of axle tubes are then shrink-fit and welded to the respective flange portions, and fitting brackets for receiving the mast pivot brackets of a fork lift mast are attached to the respective of the axle tubes.

Abstract: A hydraulic device for operating a clutch in an industrial vehicle having a transmission comprising shift changeable gears and manually operated shift levers. Gear actuating hydraulic boosters are provided for hydraulically actuating the shift changeable gears, and the clutch is actuated by a clutch cylinder. The hydraulic device comprises a clutch circuit extending between a hydraulic pump and the clutch cylinder, and a booster circuit extending between the hydraulic pump and the boosters. A gate valve is arranged in the clutch circuit and is movable in response to pressure of hydraulic oil in the booster circuit, so that the normally closed gate valve is opened when the manually operable shift levers are operated. Also, a pressure control circuit is branched from the clutch circuit and again branched into parallel third and fourth hydraulic circuits. A forward and reverse gate valve and a speed change gate valve are arranged in the third and fourth hydraulic circuits, respectively.

Abstract: A hydraulic control circuit arrangement for a single-acting cylinder provided with bottom and rod chambers separated by a piston having a piston rod extending the rod chamber, the arrangement including a directional control valve for controlling a supply of an operating oil from a hydraulic pump to the bottom chamber and an evacuation of the operating oil from both the bottom and rod chambers, a first pilot-operated valve for controlling the type of operation of the single-acting cylinder from a ram type to a piston type, and vice versa, in response to a change in an extent of a load applied to the single-acting cylinder during the lifting thereof, a short-circuiting conduit arranged between the bottom and rod chambers of the cylinder to short-circuit a flow of the operating oil from the bottom to rod chamber, and vice versa, a second pilot-operated valve located in the short-circuiting conduit to control the short-circuiting of the flow of operating oil, and a flow control valve for generating a pressure in

Abstract: A fully hydraulic power steering apparatus provided with a hydraulic power cylinder driven by turning a steering wheel to provide rear wheels of an industrial vehicle with a pivoting motion, to thereby steer the vehicle, and an error correcting unit for mechanically correcting an error between an angle of turn of the steering wheel and a corresponding stroke motion of the hydraulic power cylinder. The error correcting unit mechanically derives respective linear movements from the angle of turn of the steering wheel and the corresponding stroke of the power cylinder, and utilizes a difference between both mechanical linear movements for operating a directional control valve for controlling a flow of a pressurized oil supplied from a power steering valve unit toward the power cylinder to correct the amount of the stroke of the power cylinder with respect to the amount of angle by which the steering wheel is turned.

Abstract: An upright assembly for a fork lift truck is disclosed in which the assembly comprises an outer mast of U-shaped cross-section and an inner mast also of U-shaped cross-section that is received in the space within the outer mast. In order to keep the overall height of the upright assembly low, and to keep sliding resistance between the masts small, the inner mast is supported by an inner mast roller to counter the large forward moments and the inner mast is supported by liners to counter the small rearward moments.